REPLICor is a privately owned Canadian biopharmaceutical company developing a new antiviral technology that will revolutionize the treatment of patients with chronic hepatitis B (HBV).

Our antiviral approach blocks the release into the blood of the HBV surface antigen protein, a protein which neutralizes the patient's immune response to HBV. This approach has already been validated in the clinic where we have observed the restoration of the immune response in patients with chronic HBV. This antiviral technology promises to greatly increase the cure rate for patients when used alone or combined with existing treatments for HBV.

REPLICor is currently focusing its efforts on the clinical optimization of its technology for the treatment of chronic HBV, a disease which afflicts more than 400 million people worldwide. Once optimized, this technology will also be useful for preventing liver re-infection in patients with chronic hepatitis C undergoing liver transplantation and for the treatment of respiratory viral infections such as influenza.

Please follow the links to the left to learn more about REPLICor and its unique antiviral approach.